ArticleFrontiers in immunology2026
Serum uric acid in systemic lupus erythematosus with preserved renal function: a cross-sectional and longitudinal analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the association of serum uric acid (SUA) with established lupus nephritis (LN) and to explore its prospective association with incident LN in systemic lupus erythematosus (SLE) patients presenting with preserved renal function. Methods: We enrolled 97 SLE patients with preserved renal function (creatinine clearance ≥ 90 mL/min), including 58 with baseline LN and 39 without LN (NLN). Baseline associations were evaluated using multivariable logistic regression, with a sensitivity model further adjusting for baseline glucocorticoid dose, mycophenolate mofetil use, and cyclophosphamide use. Model discrimination was compared by Area Under the Curve (AUC) and DeLong testing. The baseline NLN cohort was followed for 3 years, and incident LN was analyzed using a Cox model adjusted for baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Results: Baseline SUA was higher in LN than in NLN patients (489.2 ± 80.8 vs. 339.8 ± 104.2 µmol/L, p < 0.001). Higher SUA remained associated with baseline LN in the main model (adjusted OR 4.20 per 1-SD increase, 95% CI 2.00-8.83, p < 0.001) and after additional adjustment for baseline treatment exposures (adjusted OR 6.32, 95% CI 1.21-32.96, p = 0.029). Adding SUA to the base clinical model increased discrimination within this dataset (AUC 0.863 to 0.929; DeLong test p = 0.001). During 3 years of follow-up, 11 NLN patients (28.2%) developed incident LN; in exploratory Cox analysis adjusted for baseline SLEDAI, higher baseline SUA was associated with a possible increased hazard of subsequent LN (adjusted HR 1.83, 95% CI 1.09-3.07, p = 0.022). Conclusion: In this dataset, SUA was associated with LN risk stratification in SLE patients with preserved renal function, but this signal may also reflect broader disease activity, systemic inflammation, and treatment-related factors. The renal specificity of SUA remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.